OraQuick(R) In-Home HIV Test Named a "Top Health Breakthrough of 2012" by Men's Health Magazine
14 2월 2013 - 8:00PM
OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral
fluid diagnostics, announced today that the Company's OraQuick®
In-Home HIV Test, the first ever in-home rapid infectious disease
test made available directly to consumers, has been named a "Top
Health Breakthrough of 2012" by Men's Health magazine. The
OraQuick® In-Home HIV Test was listed as the #1 breakthrough on
this list for 2012.
The OraQuick® In-Home HIV Test, approved by the U.S. Food and
Drug Administration (FDA) in July 2012, detects antibodies to both
HIV-1 and HIV-2 with an oral swab, providing a confidential in-home
testing option with results in as little as 20 minutes. The in-home
test, which is now available at major retailers nationwide, is an
over-the-counter version of OraQuick ADVANCE®, an oral swab rapid
test with more than 25 million units sold in the professional
market, including doctors, hospitals, clinics and other trained
professionals. The OraQuick In-Home HIV Test is available at
thousands of retailers nationwide and online at OraQuick.com.
To ensure optimal support for individuals using the OraQuick®
In-Home HIV Test, OraSure offers live support and comprehensive
referral services 24 hours a day, seven days a week, every day of
the year, through a toll-free support center and comprehensive
consumer website. The OraQuick® Support Center is staffed with
highly trained, bi-lingual (English/Spanish) representatives who
are available by telephone at 866-436-6527 to answer questions
about HIV/AIDS and using and interpreting the test. They also
provide referrals to follow-up and care, and can take orders for
the OraQuick In-Home HIV Test. Additionally, the product website
provides access to resources and referral to follow-up counseling,
confirmatory testing and medical care.
Visit OraQuick.com for more information.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture
and distribution of oral fluid diagnostic and collection devices
and other technologies designed to detect or diagnose critical
medical conditions. Its innovative products include rapid tests for
the detection of antibodies to HIV and HCV at the point of care and
testing solutions for detecting various drugs of abuse. In July
2012, the Company received approval from the U.S. Food and Drug
Administration for the Company's OraQuick® In-Home HIV Test for
sale directly to consumers in the over-the-counter (OTC) market -
making it the first and only rapid OTC HIV test approved in the
U.S. In addition, the Company is a leading provider of oral fluid
sample collection, stabilization and preparation products for
molecular diagnostic applications. OraSure's portfolio of products
is sold globally to various clinical laboratories, hospitals,
clinics, community-based organizations and other public health
organizations, research and academic institutions, distributors,
government agencies, physicians' offices, and commercial and
industrial entities. The Company's products enable healthcare
providers to deliver critical information to patients, empowering
them to make decisions to improve and protect their health.
For more information on OraSure Technologies, please visit
www.orasure.com.
The OraSure Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6440
CONTACT: Media Contact:
Jennifer Moritz
Zer0 to 5ive for OraSure Technologies
917-748-4006
jmoritz@0to5.com
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024